Skip to main content
All lobbying clients

NOVARTIS, INC.

Lobbying client · District of Columbia · filed 2025 to 2026

Multinational biopharmaceutical company

$300,000 Reported spend
6 Filings counted
1 Firms hired
6 Bills named

Spend is reported income plus in-house expenses across 6 filings. Everything on this page is grouped by the client's LDA id (196641), not by name.

 Firms hired 1
 Bills named in these filings 6
  • HR 1672
    Maintaining Investments in New Innovation Act
    5 filings
  • S 832
    EPIC Act of 2025
    4 filings
  • HR 3037
    Access to Breast Cancer Diagnosis Act of 2025
    2 filings
  • S 1500
    Access to Breast Cancer Diagnosis Act of 2025
    2 filings
  • HR 5547
    Maintaining Investments in New Innovation Act
    1 filing
  • S 476
    Maintaining Investments in New Innovation Act
    1 filing
 Reported by year 2 years
  • 2026 $100,000 2 filings
  • 2025 $200,000 4 filings
 Issues lobbied 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 2
  • HOUSE OF REPRESENTATIVES 6
  • SENATE 6
 Foreign entities disclosed 1
  • NOVARTIS INTERNATIONAL AG Switzerland named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem